Furthermore, neutralization of CD59 with the CD59 inhibitor, recombinant ILYd4, sensitized ARH-77 myeloma cells to the CDC effect mediated by rituximab (20 μg/mL) in a dose-dependent manner [64]. This evidence concerns the gene CD59 and plasma cell myeloma.